Northwire Canada EditionWednesday, July 15, 2026
Northwire
FG 0.040 +14.3% EFR 17.58 −5.5% IVN 10.50 −2.6% MASS 0.090 +0.0% NTH 0.160 −3.0% LIF 26.54 −2.4% CPAU 0.155 +0.0% PTX 0.110 +0.0% VENT 0.160 +0.0% ANK 0.280 −3.5% ODV 3.27 −3.0% MINK 0.105 +0.0% ZEN 0.660 +3.1% LCE 0.250 +4.2% CBA 0.085 +0.0% SGU 0.040 +0.0% FG 0.040 +14.3% EFR 17.58 −5.5% IVN 10.50 −2.6% MASS 0.090 +0.0% NTH 0.160 −3.0% LIF 26.54 −2.4% CPAU 0.155 +0.0% PTX 0.110 +0.0% VENT 0.160 +0.0% ANK 0.280 −3.5% ODV 3.27 −3.0% MINK 0.105 +0.0% ZEN 0.660 +3.1% LCE 0.250 +4.2% CBA 0.085 +0.0% SGU 0.040 +0.0%

← Back to our analysis

Original News Release

Pegasus Mercantile has failure-to-file CTO revoked

Ms. Meris Kott reports PEGASUS ANNOUNCES FFCTO REVOCATION FILINGS OF BOTH ANNUAL FINANCIAL STATEMENTS PLUS FIRST QUARTER RESULTS The B.C. Securities Commission has revoked the failure-to-file cease trade order that had been issued by the BCSC on Feb. 3, 2026, against the company and its securities. The company on Feb. 27, 2026, filed its audited annual financial statements, accompanying management's discussion and analysis, and chief executive officer and chief financial officer certifications for the financial year ended Sept. 30, 2025, in accordance with the regulations, and on March 2, 2026, filed its first quarter results ended Dec. 31, 2025. The revocation of the FFCTO became effective as of March 2, 2026. Pegasus has followed up with the Canadian Securities Exchange to remove the suspension of trading of its common shares, and the resumption of trading will be confirmed in a follow-up press release. The company confirms that its business has not changed and remains active, and there are no changes to its current business plan. About Pegasus Mercantile Inc. Pegasus is a prospect generator that provides high growth companies with technology, financial, operational and management assistance. The company has expanded and is entering a new phase of diversification. The focus of the company has been on global wellness, psychedelics, mycology, hemp and cannabidiol, health-care-related target companies, and their clinical studies and trials. We seek Safe Harbor.
View at source ↗